目的研究分析吉西他滨联合多西紫杉醇新辅助化疗方案在局部晚期肺癌患者中的治疗效果及其安全性评价。方法选取我院于2009年3月至2012年3月收治的77例Ⅲ期非小细胞肺癌患者,将其按照住院号尾号的奇偶分为治疗组和对照组,治疗组39例患者采用吉西他滨与多西紫杉醇联合方案,对照组38例患者采用长春瑞滨与顺铂联合方案,对比两组患者的临床效果。结果治疗组患者有效率为51.28%;对照组患者有效率为44.37%,两组患者的临床治疗效果对比有差异性,有统计学意义(P<0.05)。治疗组白细胞减少率为89.74%,血小板减少率为48.71%,恶心呕吐发生率为51.28%;对照组患者白细胞减少率为92.11%,血小板减少率为52.63%,恶心呕吐,发生率为55.26%。两组患者临床不良反应情况对比差异无显著性,无统计学意义(P>0.05)。结论吉西他滨联合多西紫杉醇新辅助化疗方案在局部晚期肺癌患者治疗中效果确切,可以作为首选方案。 Objective To study the efficacy and safety of gemcitabine combined with docetaxel neoadjuvant chemotherapy in patients with locally advanced lung cancer. Methods Totally 77 patients with stage Ⅲ non-small cell lung cancer admitted to our hospital from March 2009 to March 2012 were divided into the treatment group and the control group according to the odd-even number of the tail number of the hospitalization. The 39 patients in the treatment group received gemcitabine In combination with docetaxel, 38 patients in the control group received a combination regimen of vinorelbine and cisplatin to compare the clinical outcomes of the two groups. Results The effective rate of the treatment group was 51.28%; the effective rate of the control group was 44.37%. There was significant difference between the two groups in the clinical treatment effect (P <0.05). The treatment group leukopenia rate was 89.74%, the rate of thrombocytopenia was 48.71%, nausea and vomiting was 51.28%; control group patients with leukopenia was 92.11%, the rate of thrombocytopenia was 52.63%, nausea and vomiting, the incidence was 55.26%. There was no significant difference in clinical adverse reactions between the two groups, with no statistical significance (P> 0.05). Conclusion Gemcitabine combined with docetaxel neoadjuvant chemotherapy in patients with locally advanced lung cancer in the treatment of the exact effect, can be used as the first choice.